"MİSYONUMUZ Bilim dünyasına katkıda bulunmak amacı ile evrensel ölçekte bilgi üretmek ve bölgesel, ulusal gereksinimler doğrultusunda toplumun yaşam kalitesini yükseltmek amacı ile en üst düzey tıp eğitimi vererek ülke ve dünya gerçeklerine duyarlı, kültürel olarak donanımlı, araştırıcı ve üretici hekimler yetiştirmek. VİZYONUMUZ Ulusal ve uluslararası bilim ve teknoloji dünyası ile örgütsel bağları gelişmiş, kurumsal kültürü ve kimliği güçlü,dünyadaki nitelikli üniversiteler ile eşdeğer bir eğitim ve araştırma kurumu olmak. DEĞERLERİMİZ Bilimsellik Evrensellik Toplumsal yararlılık Çağdaşlık Yenilikçilik ve Yaratıcılık Katılımcılık Güvenilirlik"

During the past decade, Ege University Hospital conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 11 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 7 clinical trials were completed. i.e. 29.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ege University Hospital" #1 sponsor was "Ege University" with 7 trials, followed by "Incyte Corporation" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Gilead Sciences" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ege University Hospital" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Cancer Trials Ireland" with 1 trials as a collaborator and "Central European Myeloma Study Group" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Ege University Hospital" are "Beta-Thalassemia" (4 trials), "Multiple Myeloma" (3 trials), "HBV" (2 trials), "Idiopathic Pulmonary Fibrosis" (2 trials) and "Myelofibrosis" (2 trials). Many other conditions were trialed in "Ege University Hospital" in a lesser frequency.

Most popular intervention types in "Ege University Hospital" are "Drug" (31 trials), "Other" (6 trials), "Biological" (3 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Luspatercept" (3 trials), "Pembrolizumab" (3 trials), "Carboplatin" (2 trials) and "Cisplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Ege University Hospital" are 38 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Ege University Hospital". undefined are not yet recruiting, 9 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Ege University Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Ege University Hospital, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".